Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model

Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model

Background: Medullary thyroid cancer (MTC) is a rare form of cancer that affects patients’ health-related quality of life (HRQoL) and survival. Cabozantinib (Cometriq®; Ipsen, Paris, France) and vandetanib (Caprelsa®; Sanofi Genzyme, Cambridge, MA, USA) are currently the treatment modality of choice...

Full description

Bibliographic Details
Main Authors: Paul Tappenden, Christopher Carroll, Jean Hamilton, Eva Kaltenthaler, Ruth Wong, Jonathan Wadsley, Laura Moss, Sabapathy Balasubramanian
Format: Article
Language:English
Published: NIHR Journals Library 2019-02-01
Series:Health Technology Assessment
Subjects:
THYROID NEOPLASMS
MODELS
ECONOMIC
NETWORK META-ANALYSIS
Online Access:https://doi.org/10.3310/hta23080

Similar Items

Similar Items